Home Primary Antibodies Myosin Light Chain 2 Antibody [C23E15]

research use only

Myosin Light Chain 2 Antibody [C23E15]

Catalog No.: F3588

    Application: Reactivity:
    • F3588-wb
      Lane 1: Human heart, Lane 2: Human skeletal muscle, Lane 3: Mouse heart, Lane 4: Rat heart

    Usage Information

    Dilution
    1:10000
    1:600
    Application
    WB, IHC
    Reactivity
    Mouse, Rat, Human
    Source
    Rabbit Monoclonal Antibody
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    19 kDa 19 kDa
    *Why do the predicted and actual molecular weights differ?
    The following reasons may explain differences between the predicted and actual protein molecular weight.

    Datasheet & SDS

    Biological Description

    Specificity
    Myosin Light Chain 2 Antibody [C23E15] detects endogenous levels of total Myosin Light Chain 2 protein.
    Clone
    C23E15
    Synonym(s)
    MLC2; MYL2; MLC-2; MLC-2v; Cardiac myosin light chain 2; Ventricular myosin light chain 2; MLC-2s/v
    Background
    Myosin Light Chain 2 (MLC2, MYL2) is a 166-amino acid EF-hand Ca²⁺-binding regulatory light chain specifically expressed in cardiac (MLC2v) and smooth muscle, where it adopts a compact globular fold with two N-terminal EF-hand motifs for Ca²⁺/Mg²⁺ binding and a C-terminal domain that interacts with the IQ1 motif in myosin heavy chain’s neck region, working alongside the essential light chain (MLC1) at the motor-neck junction. The key phosphorylation site Ser19 is located in a flexible loop. MLC2 stabilizes myosin thick filaments and modulates actomyosin cross-bridge kinetics; phosphorylation of Ser19 by Ca²⁺/calmodulin-activated MLCK (and also by ROCK) induces a conformational switch to an extended myosin form, increasing lever arm stiffness, slowing detachment, prolonging the duty cycle, and enhancing Ca²⁺ sensitivity, thus boosting force generation during cardiac and smooth muscle contraction. Dephosphorylation by myosin phosphatase (MYPT1-PP1) enables relaxation, while non-muscle MLC2 plays roles in cytokinesis and stress fiber regulation. Mutations or knockout of MLC2 cause hypertrophic or dilated cardiomyopathy with thick filament disorganization and heart failure, and altered phosphorylation is linked to hypertension.
    References
    • https://pubmed.ncbi.nlm.nih.gov/26074085/
    • https://pubmed.ncbi.nlm.nih.gov/33606000/

    Tech Support

    Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

    Handling Instructions

    Tel: +1-832-582-8158 Ext:3
    If you have any other enquiries, please leave a message.

    * Indicates a Required Field

    Please enter your name.
    Please enter your email. Please enter a valid email address.
    Please write something to us.